

NAVIDEA BIOPHARMACEUTICALS, INC.

Form 4

November 09, 2012

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Platinum-Montaur Life Sciences, LLC

(Last) (First) (Middle)

152 W. 57TH STREET,, 4TH FLOOR

(Street)

NEW YORK, NY 10019

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

NAVIDEA
BIOPHARMACEUTICALS, INC.
[NAVB]

3. Date of Earliest Transaction (Month/Day/Year)

09/04/2012

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price |
| Common Stock, par value \$0.001 | 09/04/2012 | | S | | 205,521 | D | \$ 3.8 7,266,847 |
| Common Stock, par value \$0.001 | 09/05/2012 | | S | | 64,900 | D | \$ 3.78 7,201,947 |
| Common Stock, par | 09/06/2012 | | S | | 2,200 | D | \$ 3.71 7,199,747 |

Edgar Filing: NAVIDEA BIOPHARMACEUTICALS, INC. - Form 4

| | | | | | | | | |
|---|------------|---|---------|---|------------|-----------|---|--|
| value \$0.001 | | | | | | | | |
| Common Stock, par value \$0.001 | 09/07/2012 | S | 118,731 | D | \$ 3.61 | 7,081,016 | D | |
| Common Stock, par value \$0.001 | 09/10/2012 | S | 20,500 | D | \$ 3.75 | 7,060,516 | D | |
| Common Stock, par value \$0.001 | 09/10/2012 | S | 269,919 | D | \$ 3.69 | 6,790,597 | D | |
| Common Stock, par value \$0.001 | 09/19/2012 | S | 21,700 | D | \$ 3.22 | 6,768,897 | D | |
| Common Stock, par value \$0.001 | 09/21/2012 | S | 4,911 | D | \$ 3.24 | 6,763,986 | D | |
| Common Stock, par value \$0.001 ⁽¹⁾ | 10/10/2012 | P | 37,030 | A | \$ 2.56 | 6,801,016 | D | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 6) | | |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|-------|-----------|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or |

Number
of
Shares

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| Platinum-Montaur Life Sciences, LLC 152 W. 57TH STREET, 4TH FLOOR NEW YORK, NY 10019 | | X | | |
| Platinum Partners Value Arbitrage Fund, LP 152 WEST 57TH STREET 54TH FLOOR NEW YORK, NY 10019 | | X | | |

Signatures

/s/ OLIVER
JIMENEZ

11/09/2012

__Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The reporting persons' sale at a price of \$3.80 per share on September 4, 2012 of Common Stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 37,030 shares, with the reporting persons' purchase of shares of

- (1) Common Stock at a price of \$2.56 per share on October 10, 2012 reported herein. The reporting persons have agreed to pay to Navidea Biopharmaceuticals, Inc., \$45,472.84, representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.